Marinus Pharmaceuticals Shares Are Trading Lower After the Company Announced Its Phase 3 TrustTSC Trial of Oral Ganaxolone Did Not Meet Its Primary Endpoint.
Marinus Pharmaceuticals Shares Are Trading Lower After the Company Announced Its Phase 3 TrustTSC Trial of Oral Ganaxolone Did Not Meet Its Primary Endpoint.
marinus pharmaceuticals股價下跌,因公司宣佈其口服Ganaxolone第3期TrustTSC試驗未達到主要終點。
Marinus Pharmaceuticals Shares Are Trading Lower After the Company Announced Its Phase 3 TrustTSC Trial of Oral Ganaxolone Did Not Meet Its Primary Endpoint.
marinus pharmaceuticals股價下跌,因公司宣佈口服加納左烯三相TrustTSC試驗未達到主要終點。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。